Cancer is a disease of your cells, and sorting out your cancer from all others is a daunting challenge but one that cancer cell biologists are furiously pursuing. In the Age of Personalized Medicine, we've learned that one size doesn't fit all, least of all in cancer.
They are examining every aspect of cell function and cell structure, looking for clusters of phenotypes that could label a patient's cancer so precisely that it could be linked to therapies proven effective against just that type. The latest frontier in this search for cancer telltales is the cellular process of endocytosis, which is the way cells take outside materials like proteins inside.
Endocytosis is not normal in cancer cells but how dysregulated the process is in cancer cells has just been revealed by Sarah Elkin and colleagues in the University of Texas (UT) Southwestern Medical Center lab of Sandra Schmid. The researchers used three endocytic pathways as markers to sort out 29 non-small cell lung cancer (NSCLC) lines into two distinct clusters characterized by their endocytic dysfunction. Elkin will present Tuesday, December 15, at ASCB 2015 in San Diego on the work published1 last month in Cancer Research.
But by hierarchical clustering of observed alterations in endocytosis, the researchers identified two distinct cancer phenotype clusters, one marked by mutations in the oncogene KRAS in mesenchymal cells and the other by changes in epithelial cells.
Their results, say the UT Southwestern researchers, show that changes in endocytosis reflected by the expression of important molecules on the cell surface can be used to distinguish cancer subtypes. But they also warn that their work shows the danger of drawing general conclusions about cancer-relevant phenotypes from a single cancer cell line. Cancer can be chillingly personal, right down to your cell surface.